# Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer

> **NCT00189670** · PHASE2 · COMPLETED · sponsor: **Association Européenne de Recherche en Oncologie**

## Conditions studied

- Node Positive Breast Cancer

## Interventions

- **PROCEDURE:** 6 TEC q 3 weeks
- **PROCEDURE:** 4 EC q 2 weeks followed by 4 TXT q 2 weeks
- **PROCEDURE:** 4 TXT q 2 weeks followed by 4 EC q 2 weeks

## Key facts

- **NCT ID:** NCT00189670
- **Lead sponsor:** Association Européenne de Recherche en Oncologie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-09-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189670, "Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00189670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*